Generic substitution of antiepileptic drugs
- PMID: 21091318
- DOI: 10.1586/ern.10.163
Generic substitution of antiepileptic drugs
Abstract
Substitution of antiepileptic drugs with generic formulations may affect individual people, as well as healthcare systems. Analyses of large medical claims databases suggest that generic substitution of antiepileptic drugs is associated with increased morbidity and greater use of healthcare resources. While a single brand-to-generic switch may be associated with a slight increase in overall medical costs, multiple switches may be associated with higher costs, perhaps because different generic agents are not required to be bioequivalent to each other. Generic substitution also affects the individual: along with the possible increased risk of seizures or adverse events, inconsistency of supply may make the medication appear unfamiliar, thus discouraging adherence. Importantly, substitution is often carried out at the dispensing level, without the knowledge or consent of physicians and affected individuals. Therefore, regulatory and professional bodies advocate that substitution should not be carried out without specific counseling of the individual by healthcare professionals on the details and implications of the change.
Similar articles
-
Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.Epilepsia. 2006;47 Suppl 5:16-20. doi: 10.1111/j.1528-1167.2006.00871.x. Epilepsia. 2006. PMID: 17239100
-
The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.Expert Opin Pharmacother. 2009 Oct;10(14):2317-28. doi: 10.1517/14656560903140525. Expert Opin Pharmacother. 2009. PMID: 19663636 Review.
-
Prescribing generic antiepileptic drugs: Issues and concerns for nurse practitioners.J Am Acad Nurse Pract. 2010 Jun;22(6):300-4. doi: 10.1111/j.1745-7599.2010.00511.x. J Am Acad Nurse Pract. 2010. PMID: 20536627 Review.
-
Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy.Epilepsy Behav. 2005 Aug;7(1):98-105. doi: 10.1016/j.yebeh.2005.04.005. Epilepsy Behav. 2005. PMID: 15961350 Clinical Trial.
-
Generic substitution in the treatment of epilepsy: patient and physician perceptions.Epilepsy Behav. 2008 Nov;13(4):693-9. doi: 10.1016/j.yebeh.2008.06.001. Epub 2008 Sep 10. Epilepsy Behav. 2008. PMID: 18589000
Cited by
-
Recommendations for the treatment of epilepsy in adult patients in general practice in Belgium: an update.Acta Neurol Belg. 2012 Jun;112(2):119-31. doi: 10.1007/s13760-012-0070-9. Epub 2012 Apr 28. Acta Neurol Belg. 2012. PMID: 22544726 Free PMC article.
-
Adherence to changing from brand-name to generic atorvastatin in newly treated patients: a retrospective cohort study using health insurance claims.J Pharm Health Care Sci. 2015 Apr 1;1:12. doi: 10.1186/s40780-015-0013-8. eCollection 2015. J Pharm Health Care Sci. 2015. PMID: 26819723 Free PMC article.
-
Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.JAMA Neurol. 2017 Aug 1;74(8):919-926. doi: 10.1001/jamaneurol.2017.0497. JAMA Neurol. 2017. PMID: 28654954 Free PMC article. Clinical Trial.
-
Generic switching and non-persistence among medicine users: a combined population-based questionnaire and register study.PLoS One. 2015 Mar 16;10(3):e0119688. doi: 10.1371/journal.pone.0119688. eCollection 2015. PLoS One. 2015. PMID: 25775472 Free PMC article.
-
Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain.Clinicoecon Outcomes Res. 2015 Jun 4;7:299-312. doi: 10.2147/CEOR.S85756. eCollection 2015. Clinicoecon Outcomes Res. 2015. PMID: 26082655 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical